[Acute lymphatic leukemia in adults. Therapy and prognosis in comparison with acute myelogenous leukemia].
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D001215:Asparaginase / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D010291:Paresis / Q000139:chemically induced; D011379:Prognosis; D011879:Radiotherapy Dosage; D012075:Remission, Spontaneous; D014750:Vincristine / Q000627:therapeutic use
D003561:Cytarabine; D014750:Vincristine; D015122:Mercaptopurine; D001215:Asparaginase; D008775:Methylprednisolone; D008727:Methotrexate; D003630:Daunorubicin
Akute lymphatische Lelkämie des Erwaschsenen. Therapie und Prognose im Vergleich zur akuten myelogenen Leukämie.